Literature DB >> 19885294

Group of signs: a new method to evaluate glycemic variability.

Francesco Zaccardi1, Paola Di Stefano, Elena Busetto, Marco Orsini Federici, Andrea Manto, Fabio Infusino, Gaetano Antonio Lanza, Dario Pitocco, Giovanni Ghirlanda.   

Abstract

BACKGROUND: Glycemic variability is an important parameter used to resolve potential clinical problems in diabetic patients. It is known that glycemic variability generates oxidative stress and potentially contributes to the development of macro- and microvascular complications in diabetes. By controlling glycemic variability, it is possible to reduce these complications and to set the therapy for all patients with diabetes. The aims of this study were to (1) propose a new standardized, objective, and flexible approach to measure glycemic variability by a continuous glucose monitoring system (CGMS)-the group of signs (GOS) method; (2) compare the correlation between mean amplitude of glucose excursion (MAGE), a well-known index of glycemic variability calculated by the physician and the MAGE defined with the GOS method, in order to validate the GOS; and (3) suggest new indexes of glycemic variability.
METHODS: We tested the GOS algorithm on data collected by a CGMS every 5 minutes for 24 hours on 50 patients. Consequently, for 8 patients we calculated and compared the physician's MAGE in the standard way and by the GOS method.
RESULTS: Comparison between the two methods has shown high correlations, from a minimum correlation of 86% to a maximum of 98%, with p values <0.01 (Pearson test).
CONCLUSIONS: Preliminary data suggest that the proposed algorithm is a valid, efficient, and reliable method able to calculate the standard MAGE on CGMS data systematically and to create other alternative glycemic variability indexes.

Entities:  

Keywords:  continuous glucose monitoring system; diabetic complications; glycemic variability; indices of variability

Year:  2008        PMID: 19885294      PMCID: PMC2769822          DOI: 10.1177/193229680800200614

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  27 in total

1.  Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study.

Authors:  M Muggeo; G Zoppini; E Bonora; E Brun; R C Bonadonna; P Moghetti; G Verlato
Journal:  Diabetes Care       Date:  2000-01       Impact factor: 19.112

2.  Evaluation of a new measure of blood glucose variability in diabetes.

Authors:  Boris P Kovatchev; Erik Otto; Daniel Cox; Linda Gonder-Frederick; William Clarke
Journal:  Diabetes Care       Date:  2006-11       Impact factor: 19.112

3.  The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years.

Authors:  M Coutinho; H C Gerstein; Y Wang; S Yusuf
Journal:  Diabetes Care       Date:  1999-02       Impact factor: 19.112

4.  Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.

Authors:  M Shichiri; H Kishikawa; Y Ohkubo; N Wake
Journal:  Diabetes Care       Date:  2000-04       Impact factor: 19.112

5.  Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation.

Authors:  Lisa Quagliaro; Ludovica Piconi; Roberta Assaloni; Lucia Martinelli; Enrico Motz; Antonio Ceriello
Journal:  Diabetes       Date:  2003-11       Impact factor: 9.461

6.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

7.  Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program.

Authors:  R P Donahue; R D Abbott; D M Reed; K Yano
Journal:  Diabetes       Date:  1987-06       Impact factor: 9.461

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

10.  The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial.

Authors: 
Journal:  Diabetes       Date:  1995-08       Impact factor: 9.461

View more
  8 in total

1.  Test-retest reliability of a continuous glucose monitoring system in individuals with type 2 diabetes.

Authors:  Tasuku Terada; Sarah Loehr; Emmanuel Guigard; Linda J McCargar; Gordon J Bell; Peter Senior; Normand G Boulé
Journal:  Diabetes Technol Ther       Date:  2014-05-09       Impact factor: 6.118

2.  Evaluation of glycemic variability in well-controlled type 2 diabetes mellitus.

Authors:  Suk Chon; Yun Jung Lee; Gemma Fraterrigo; Paolo Pozzilli; Moon Chan Choi; Mi-Kwang Kwon; Sang Ouk Chin; Sang Youl Rhee; Seungjoon Oh; Young-Seol Kim; Jeong-Taek Woo
Journal:  Diabetes Technol Ther       Date:  2013-04-25       Impact factor: 6.118

3.  Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes.

Authors:  Gong Su; Shuhua Mi; Hong Tao; Zhao Li; Hongxia Yang; Hong Zheng; Yun Zhou; Changsheng Ma
Journal:  Cardiovasc Diabetol       Date:  2011-02-25       Impact factor: 9.951

4.  Glycemic Variability Assessed by Continuous Glucose Monitoring and Short-Term Outcome in Diabetic Patients Undergoing Percutaneous Coronary Intervention: An Observational Pilot Study.

Authors:  Annunziata Nusca; Angelo Lauria Pantano; Rosetta Melfi; Claudio Proscia; Ernesto Maddaloni; Rocco Contuzzi; Fabio Mangiacapra; Andrea Palermo; Silvia Manfrini; Paolo Pozzilli; Germano Di Sciascio
Journal:  J Diabetes Res       Date:  2015-07-26       Impact factor: 4.011

5.  Effects of vildagliptin compared with glibenclamide on glucose variability after a submaximal exercise test in patients with type 2 diabetes: study protocol for a randomized controlled trial, DIABEX VILDA.

Authors:  Aline Fofonka; Jorge Pinto Ribeiro; Karina Rabello Casali; Beatriz D Schaan
Journal:  Trials       Date:  2014-11-04       Impact factor: 2.279

6.  Long-term Effect of Islet Transplantation on Glycemic Variability.

Authors:  Federico Bertuzzi; Luciano De Carlis; Mario Marazzi; Antonio Gaetano Rampoldi; Matteo Bonomo; Barbara Antonioli; Marta Cecilia Tosca; Marta Galuzzi; Andrea Lauterio; Danila Fava; Patrizia Dorighet; Andrea De Gasperi; Giacomo Colussi
Journal:  Cell Transplant       Date:  2018-06-05       Impact factor: 4.064

7.  Altered muscle mitochondrial, inflammatory and trophic markers, and reduced exercise training adaptations in type 1 diabetes.

Authors:  Dean Minnock; Giosuè Annibalini; Giacomo Valli; Roberta Saltarelli; Mauricio Krause; Elena Barbieri; Giuseppe De Vito
Journal:  J Physiol       Date:  2022-01-24       Impact factor: 6.228

8.  Aerobic and combined exercise sessions reduce glucose variability in type 2 diabetes: crossover randomized trial.

Authors:  Franciele R Figueira; Daniel Umpierre; Karina R Casali; Pedro S Tetelbom; Nicoli T Henn; Jorge P Ribeiro; Beatriz D Schaan
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.